- Home
- PLX vs GLSI Comparison
PLX vs GLSI Comparison
Compare PLX & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | GLSI |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | United States | United States |
| Employees | 226 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 187.9M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLX | GLSI |
|---|---|---|
| Price | $2.34 | $13.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 489.5K | 168.2K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.42 | $7.78 |
| 52 Week High | $3.19 | $34.10 |
Technical Indicators
Market Signals| Indicator | PLX | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 45.20 | 35.75 |
| Support Level | $2.25 | $12.51 |
| Resistance Level | $2.44 | $14.19 |
| Average True Range (ATR) | 0.10 | 1.73 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 21.15 | 16.00 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.